Vaccines
We offer a complete line of Vaccines
Astra Zeneca
CSL Seqirus
Dynavax
GSK
Merck
Merck/Sanofi Pasteur (MSP)
Moderna
Novavax
Pfizer
Sanofi
Who Is AstraZeneca?
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas: Oncology; Cardiovascular, Renal & Metabolism; and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
When was AstraZeneca Founded?
Astra was founded in Sweden in 1913. Zeneca Group PLC was formed when ICI demerged three of its businesses. In 1999 Astra and Zeneca merge, creating AstraZeneca.
Where is AstraZeneca Located?
AstraZeneca is headquartered in Cambridge, United Kingdom with two primary locations in North America – Gaithersburg, Maryland and Wilmington, Delaware – where the majority of their US employees come together on global projects.
Who Owns AstraZeneca?
The largest shareholders of AstraZeneca are owned by institutional investors including T. Rowe Price Associates, Inc, Wellington Management Co. LLP, PRIMECAP Management Co, Capital Research & Management Company, GQG Partners LLC, Jennison Associates LLC, and Fidelity Management & Research Company.
What Vaccines Are Made By AstraZeneca?
AstraZeneca is the maker of FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal), an intranasal vaccine for active immunization of persons 2-49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. It is also known as LAIV (Live Attenuated Intranasal Vaccine).
FluMist® Quadrivalent is contraindicated in persons who have had a severe allergic reaction (eg, anaphylaxis) to any vaccine component, including egg protein, or after a previous dose of any influenza vaccine, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy. Most common side effects reported were runny nose or nasal congestion, sore throat, and fever >100°F. For additional Important Safety Information and full Prescribing Information, visit here.
Flumist is sold through distributors. Medical Practices interested in adding Flumist ( LAIV ) to their flu vaccine offerings can receive additional benefits on Flumist purchases through an ABS membership.
References: 1. Grohskopf LA, Alyanak E, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices — United States, 2019-20 influenza season. MMWR. 2019;68:1–21.
AAP News. No flu vaccine preference for 2019-’20 season. https://www.aapublications.org/news. Accessed 11/7/19. FLUMIST is a registered trademark of the AstraZeneca group of companies. ©2019 AstraZeneca. All rights reserved. US-34627 Last Updated 12/19
AstraZeneca Vaccines Ordering
For information regarding influenza, ordering, dosing and administration of FluMist® Quadrivalent, and recommendations from the AAP and ACIP, visit here.
For reimbursement support services for FluMist® Quadrivalent, visit here.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas: Oncology; Cardiovascular, Renal & Metabolism; and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
When was AstraZeneca Founded?
Astra was founded in Sweden in 1913. Zeneca Group PLC was formed when ICI demerged three of its businesses. In 1999 Astra and Zeneca merge, creating AstraZeneca.
Where is AstraZeneca Located?
AstraZeneca is headquartered in Cambridge, United Kingdom with two primary locations in North America – Gaithersburg, Maryland and Wilmington, Delaware – where the majority of their US employees come together on global projects.
Who Owns AstraZeneca?
The largest shareholders of AstraZeneca are owned by institutional investors including T. Rowe Price Associates, Inc, Wellington Management Co. LLP, PRIMECAP Management Co, Capital Research & Management Company, GQG Partners LLC, Jennison Associates LLC, and Fidelity Management & Research Company.
What Vaccines Are Made By AstraZeneca?
AstraZeneca is the maker of FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal), an intranasal vaccine for active immunization of persons 2-49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. It is also known as LAIV (Live Attenuated Intranasal Vaccine).
FluMist® Quadrivalent is contraindicated in persons who have had a severe allergic reaction (eg, anaphylaxis) to any vaccine component, including egg protein, or after a previous dose of any influenza vaccine, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy. Most common side effects reported were runny nose or nasal congestion, sore throat, and fever >100°F. For additional Important Safety Information and full Prescribing Information, visit here.
Flumist is sold through distributors. Medical Practices interested in adding Flumist ( LAIV ) to their flu vaccine offerings can receive additional benefits on Flumist purchases through an ABS membership.
References: 1. Grohskopf LA, Alyanak E, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices — United States, 2019-20 influenza season. MMWR. 2019;68:1–21.
AAP News. No flu vaccine preference for 2019-’20 season. https://www.aapublications.org/news. Accessed 11/7/19. FLUMIST is a registered trademark of the AstraZeneca group of companies. ©2019 AstraZeneca. All rights reserved. US-34627 Last Updated 12/19
AstraZeneca Vaccines Ordering
For information regarding influenza, ordering, dosing and administration of FluMist® Quadrivalent, and recommendations from the AAP and ACIP, visit here.
For reimbursement support services for FluMist® Quadrivalent, visit here.
Who Is CSL Seqirus?
CSL Seqirus is a trusted partner for businesses in the field of flu vaccine administration, and their platform, flu360®, serves as a comprehensive solution to support flu vaccination businesses throughout the year.
With flu360, CSL Seqirus aims to make the process of administering flu vaccines as effortless as possible. They offer year-round flu campaign coverage, ensuring that businesses have the necessary support to successfully carry out their flu vaccination programs.
Through their flu360 platform, CSL Seqirus is committed to supporting businesses involved in flu vaccine administration. By offering year-round flu campaign coverage and a range of solutions that address clinical, financial, and operational aspects, flu360 aims to make the business of flu vaccine administration easier and more efficient for their partners.
Please let us know if you would like to learn more about Seqirus and we will have a representative reach out.
Where is CSL Seqirus Located?
CSL Seqirus’ U.S. Headquarters is located in Holly Springs, North Carolina, USA.
What Year was CSL Seqirus Founded?
CSL Seqirus was founded in 1916.
Who is CSL Seqirus Owned By?
CSL Behring’s parent company, CSL Limited, is headquartered in Melbourne, Victoria, Australia.
Who is on the CSL Seqirus Leadership Team?
Paul McKenzie is Chief Executive Officer and Managing Director of CSL Seqirus.
What is CSL Seqirus Famous For?
SL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since their start in 1916, they have been driven by their promise to save lives using the latest technologies.
What Flu Vaccine Products Does CSL Seqirus Have Available Today?
CSL Seqirus offers the following influenza vaccines:
What Are The Benefits of Using the CSL Seqirus flu360 Platform?
One key aspect of flu360 is its focus on providing comprehensive support across various areas of the flu vaccination business.
CSL Seqirus offers flu360 Solutions, which encompass clinical support, financial guidance, and operational efficiency.
CSL Seqirus Vaccines Ordering and Cost Savings With ABS
Please let us know if you would like to learn more about Seqirus and we will have a representative reach out.
Receiving contracted discounts on Seqirus’s influenza vaccine may to be done through an ABS membership. When establishing a direct purchase account with Seqirus at flu360.com, and placing orders for FLUAD®, FLUCELVAX® and AFLURIA®, please remember to notify Seqirus of your membership in Medical Practice Purchasing Group, ABS.
CSL Seqirus is a trusted partner for businesses in the field of flu vaccine administration, and their platform, flu360®, serves as a comprehensive solution to support flu vaccination businesses throughout the year.
With flu360, CSL Seqirus aims to make the process of administering flu vaccines as effortless as possible. They offer year-round flu campaign coverage, ensuring that businesses have the necessary support to successfully carry out their flu vaccination programs.
Through their flu360 platform, CSL Seqirus is committed to supporting businesses involved in flu vaccine administration. By offering year-round flu campaign coverage and a range of solutions that address clinical, financial, and operational aspects, flu360 aims to make the business of flu vaccine administration easier and more efficient for their partners.
Please let us know if you would like to learn more about Seqirus and we will have a representative reach out.
Where is CSL Seqirus Located?
CSL Seqirus’ U.S. Headquarters is located in Holly Springs, North Carolina, USA.
What Year was CSL Seqirus Founded?
CSL Seqirus was founded in 1916.
Who is CSL Seqirus Owned By?
CSL Behring’s parent company, CSL Limited, is headquartered in Melbourne, Victoria, Australia.
Who is on the CSL Seqirus Leadership Team?
Paul McKenzie is Chief Executive Officer and Managing Director of CSL Seqirus.
What is CSL Seqirus Famous For?
SL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since their start in 1916, they have been driven by their promise to save lives using the latest technologies.
What Flu Vaccine Products Does CSL Seqirus Have Available Today?
CSL Seqirus offers the following influenza vaccines:
FLUAD QUADRIVALENT
The first-and-only adjuvanted quadrivalent seasonal influenza vaccine approved for patients 65+ years.FLUCELVAX QUADRIVALENT
The first-and-only cell-based flu vaccine approved for the prevention of influenza in patients 6+ months.AFLURIA® QUADRIVALENT (Influenza Vaccine) 6+months
A quadrivalent influenza vaccine for the prevention of seasonal influenza in patients 6+ months.What Are The Benefits of Using the CSL Seqirus flu360 Platform?
One key aspect of flu360 is its focus on providing comprehensive support across various areas of the flu vaccination business.
CSL Seqirus offers flu360 Solutions, which encompass clinical support, financial guidance, and operational efficiency.
Clinical Support
In terms of clinical support, flu360 provides resources that streamline and strengthen immunization clinics throughout the year, going beyond just the flu shot ingredients. This ensures that businesses have the necessary tools and knowledge to run efficient and effective immunization clinics.Financial Guidance
Additionally, flu360 offers financial guidance, simplifying the process of ordering, coding, billing, and reimbursements, allowing businesses to prioritize their patients and influenza vaccinations without delays.Operational Efficiency
Furthermore, flu360 enhances operational efficiency by providing solutions to address day-to-day operational burdens and inventory management challenges, ultimately increasing overall efficiency and productivity for flu vaccination businesses.CSL Seqirus Vaccines Ordering and Cost Savings With ABS
Please let us know if you would like to learn more about Seqirus and we will have a representative reach out.
Receiving contracted discounts on Seqirus’s influenza vaccine may to be done through an ABS membership. When establishing a direct purchase account with Seqirus at flu360.com, and placing orders for FLUAD®, FLUCELVAX® and AFLURIA®, please remember to notify Seqirus of your membership in Medical Practice Purchasing Group, ABS.
Dynavax
HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.1 HEPLISAV-B is the first and only 2 dose hepatitis B vaccine for Adults ≥ 18 years.
HEPLISAV-B is recommended by the CDC Advisory Committee on Immunization Practices (ACIP) for the Prevention of Hepatitis B in Adults.
If you would like to learn more about HEPLISAV-B, please let us know and we will have a representative reach out to you. You may also call 1-84-HEPLISAV 1-844-375-4728, or go to their website heplisavbhcp.com and click on “request information” on the top right hand corner of the page to have a representative reach out to your office.
HEPLISAV-B is only available through authorized distributors including Vaccine Shoppe and Vaxserve. For a complete list, please call 1-84-HEPLISAV (1-844-375-4728).
IMPORTANT SAFETY INFORMATION
Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.
Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.
Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.
Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.
The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).
References: 1. HEPLISAV-B [package insert]. Berkeley, CA: Dynavax Technologies Corporation; 2017.2. Dynavax’s HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults [news release]. Berkeley CA: Dynavax Technologies Corporation. http://investors.dynavax.com/news-releases/newsrelease-details/dynavaxs-heplisav-btm-hepatitis-b-vaccine-recombinant-adjuvanted. Accessed March 15, 2018.
US-18-01-00342
HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.1 HEPLISAV-B is the first and only 2 dose hepatitis B vaccine for Adults ≥ 18 years.
HEPLISAV-B is recommended by the CDC Advisory Committee on Immunization Practices (ACIP) for the Prevention of Hepatitis B in Adults.
If you would like to learn more about HEPLISAV-B, please let us know and we will have a representative reach out to you. You may also call 1-84-HEPLISAV 1-844-375-4728, or go to their website heplisavbhcp.com and click on “request information” on the top right hand corner of the page to have a representative reach out to your office.
HEPLISAV-B is only available through authorized distributors including Vaccine Shoppe and Vaxserve. For a complete list, please call 1-84-HEPLISAV (1-844-375-4728).
IMPORTANT SAFETY INFORMATION
Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.
Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.
Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.
Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.
The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).
References: 1. HEPLISAV-B [package insert]. Berkeley, CA: Dynavax Technologies Corporation; 2017.2. Dynavax’s HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults [news release]. Berkeley CA: Dynavax Technologies Corporation. http://investors.dynavax.com/news-releases/newsrelease-details/dynavaxs-heplisav-btm-hepatitis-b-vaccine-recombinant-adjuvanted. Accessed March 15, 2018.
US-18-01-00342
Who Is GSK?
GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.
Why GSK?
What Vaccines Are Made By GSK?
GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.
Why GSK?
GSK’s goal is to positively impact the health of 2.5 billion people by the end of the decade.
What Vaccines Are Made By GSK?
- Arexvy
- Bexero
- Boostrix
- Engerix-B
- Havrix
- Hiberix
- Infanrix
- Kinrix
- Menveo
- Pediarix
- Priorix (MMR)
- Rotarix
- Shingrix
- Twinrix
Who Is Merck?
Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs to help deliver them to the people who need them. Merck delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products.
Why Merck?
What Is a Merck Vaccine?
Merck Vaccines History
What Vaccines Are Made By Merck?
Merck Vaccines List – The following adult, adolescent and pediatric vaccines are available.
Where Is Merck From?
Merk’s global group headquarters is in Darmstadt, Germany with the Merck U.S. corporate headquarters in Rahway, New Jersey.
Who Owns Merck?
Institutional investors hold a majority ownership of Merck & Co, Inc. through the 77.22% of the outstanding shares that they control.
Merck Vaccines Ordering
ABS is pleased to offer significant savings directly from Merck or via (800) MerckRx (800-637-2579) . The vaccines below are available at a discount. Your practice may realize an additional 2% savings by paying promptly. Due to product pricing confidentiality, we ask that you contact your Merck sales representatives or ABS to obtain product quotations.
Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs to help deliver them to the people who need them. Merck delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products.
Why Merck?
Merck has been discovering, developing, supplying and delivering vaccines to help prevent disease around the world for over 130 years. In 2022 alone, they manufactured and distributed approximately 203 million doses. Their work in researching and producing vaccines is guided by science and fueled by human need.
It is no secret that inventing and developing vaccines is complex, time intensive and carries no guarantees. It takes active collaboration by teams who partner with governments, academic researchers and non-government organizations around the world.
What Is a Merck Vaccine?
Vaccines are one of the greatest public health success stories in history and help protect against more than 20 potentially life-threatening diseases. Merck produces 10 of the 18 serious diseases for which the CDC recommends routine vaccination.
Merck Vaccines History
Merck & Co. was founded in the U.S. on January 1, 1891. George Merck, age 23, established the company to distribute fine chemicals throughout New York City and the neighboring areas. In 1933 The Merck Research Laboratory was founded in Rahway, New Jersey. The laboratory represented Merck’s initial foray into pharmacological research. In 1977, the first pneumonia vaccine was approved, Merck’s PNEUMOVAX. In 1986, Merck’s recombinant Hepatitis B vaccine RECOMBIVAX HB was approved by the FDA, the first recombinant vaccine for human use.
What Vaccines Are Made By Merck?
Merck Vaccines List – The following adult, adolescent and pediatric vaccines are available.
- VAXNEUVANCE™
- MMRII
- GARDASIL®9 (HPV9)
- VARIVAX® (VZV)
- RotaTeq® (RV5)
- RECOMBIVAX HB® (HepB) – Peds/Adolescent and Adult
- TVAQTA® (HepA) – Pediatric and Adult
- ProQuad® (MMRV)
- PNEUMOVAX® 23 (PPSV23)
- PedvaxHIB® (PRP-OMP)
Where Is Merck From?
Merk’s global group headquarters is in Darmstadt, Germany with the Merck U.S. corporate headquarters in Rahway, New Jersey.
Who Owns Merck?
Institutional investors hold a majority ownership of Merck & Co, Inc. through the 77.22% of the outstanding shares that they control.
Merck Vaccines Ordering
ABS is pleased to offer significant savings directly from Merck or via (800) MerckRx (800-637-2579) . The vaccines below are available at a discount. Your practice may realize an additional 2% savings by paying promptly. Due to product pricing confidentiality, we ask that you contact your Merck sales representatives or ABS to obtain product quotations.
Purchase Merck products directly from their website.
Who is Merck/Sanofi Pasteur (MSP)?
Sanofi Pasteur MSD is a joint venture owned on a 50/50 basis by Sanofi Pasteur (the vaccine division of Sanofi) and Merck (known as MSD outside the United States and Canada). It was created in 1994 to develop and commercialize vaccines originating from both companies’ pipelines to improve and promote public health in 19 European countries. Over the past twenty years, Sanofi Pasteur MSD has launched numerous innovative vaccines originating from Sanofi Pasteur and MSD’s development pipelines, addressing key unmet medical needs and helping to protect millions of lives.
What is VaxelisTM Vaccine?
Vaxelis™ the much anticipated hexavalent vaccine developed collaboratively between Merck & Sanofi Pasteur is finally available through ABS!
VaxelisTM is a hexavalent combination vaccine approved to prevent diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b, and hepatitis B.
When Was VaxelisTM Approved?
Approved by the FDA in 2018 and given the recommendation by the ACIP, Vaxelis™ will be an important leap forward in reducing the number of injections required for infant immunization.
Preferred VaxelisTM Pricing Now Available Through ABS
The Vaxelis™ pricing program is a separate and new contract from other Sanofi Pasteur vaccines. For member practices who are interested in qualifying for the performance pricing, there is a marketshare component. For details please reach out to us at (818) 332-7057 or by e-mail at ten.gppm@ofni.
ABS Members may participate in the Vaxelis™ performance pricing program by completing the performance pricing form.
More details about Vaxelis™ may be found at website www.vaxelis.com
Who Makes VaxelisTM?
VaxelisTM is produced by Sanofi Pasteur MSD. The combined expertise resulting from Sanofi Pasteur and Merck’s research to focus on the development of new vaccines in Europe in order to produce the most effective, most acceptable and better tolerated vaccines. For more information visit: http://www.spmsd.com
What Does VaxelisTM Replace?
While two pentavalent vaccines, Pentacel® and Pediarix®, have been common options for reducing the number of shots in the infant vaccination series, VaxelisTM represents the first six-component version.
Can VaxelisTM be Used For Catch Up?
Yes, VaxelisTM can be used for older children behind on their immunization schedule. The vaccine may be used for children younger than age 5 requiring a catch-up primary series, using appropriate minimum intervals. It is not approved as the booster dose of DTaP [dose 4 or 5] or IPV [dose 4] or Hib [dose 4]. If VaxelisTM is inadvertently given as a booster dose, it may count as valid and does not need to be repeated.
Is VaxelisTM Interchangeable? (VaxelisTM With Other Vaccines)
VaxelisTM can be administered at the same visit with other vaccines, but in separate syringes. Specifically, it should not be mixed with or used to reconstitute any other vaccine. Discard unused portions. VaxelisTM is a suspension for injection available in 0.5 mL single-dose vials and prefilled syringes.
Can VaxelisTM be Given After Pentacel®? (Is VaxelisTM Interchangeable With Pentacel®?)
VaxelisTM may be used to complete the first 3 doses of the 5-dose DTaP series in infants and children who have received 1 or 2 doses of Pentacel® or Daptacel® and are also scheduled to receive the other antigens in VaxelisTM.
Sanofi Pasteur MSD is a joint venture owned on a 50/50 basis by Sanofi Pasteur (the vaccine division of Sanofi) and Merck (known as MSD outside the United States and Canada). It was created in 1994 to develop and commercialize vaccines originating from both companies’ pipelines to improve and promote public health in 19 European countries. Over the past twenty years, Sanofi Pasteur MSD has launched numerous innovative vaccines originating from Sanofi Pasteur and MSD’s development pipelines, addressing key unmet medical needs and helping to protect millions of lives.
What is VaxelisTM Vaccine?
Vaxelis™ the much anticipated hexavalent vaccine developed collaboratively between Merck & Sanofi Pasteur is finally available through ABS!
VaxelisTM is a hexavalent combination vaccine approved to prevent diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b, and hepatitis B.
When Was VaxelisTM Approved?
Approved by the FDA in 2018 and given the recommendation by the ACIP, Vaxelis™ will be an important leap forward in reducing the number of injections required for infant immunization.
Preferred VaxelisTM Pricing Now Available Through ABS
The Vaxelis™ pricing program is a separate and new contract from other Sanofi Pasteur vaccines. For member practices who are interested in qualifying for the performance pricing, there is a marketshare component. For details please reach out to us at (818) 332-7057 or by e-mail at ten.gppm@ofni.
ABS Members may participate in the Vaxelis™ performance pricing program by completing the performance pricing form.
More details about Vaxelis™ may be found at website www.vaxelis.com
Who Makes VaxelisTM?
VaxelisTM is produced by Sanofi Pasteur MSD. The combined expertise resulting from Sanofi Pasteur and Merck’s research to focus on the development of new vaccines in Europe in order to produce the most effective, most acceptable and better tolerated vaccines. For more information visit: http://www.spmsd.com
What Does VaxelisTM Replace?
While two pentavalent vaccines, Pentacel® and Pediarix®, have been common options for reducing the number of shots in the infant vaccination series, VaxelisTM represents the first six-component version.
Can VaxelisTM be Used For Catch Up?
Yes, VaxelisTM can be used for older children behind on their immunization schedule. The vaccine may be used for children younger than age 5 requiring a catch-up primary series, using appropriate minimum intervals. It is not approved as the booster dose of DTaP [dose 4 or 5] or IPV [dose 4] or Hib [dose 4]. If VaxelisTM is inadvertently given as a booster dose, it may count as valid and does not need to be repeated.
Is VaxelisTM Interchangeable? (VaxelisTM With Other Vaccines)
VaxelisTM can be administered at the same visit with other vaccines, but in separate syringes. Specifically, it should not be mixed with or used to reconstitute any other vaccine. Discard unused portions. VaxelisTM is a suspension for injection available in 0.5 mL single-dose vials and prefilled syringes.
Can VaxelisTM be Given After Pentacel®? (Is VaxelisTM Interchangeable With Pentacel®?)
VaxelisTM may be used to complete the first 3 doses of the 5-dose DTaP series in infants and children who have received 1 or 2 doses of Pentacel® or Daptacel® and are also scheduled to receive the other antigens in VaxelisTM.
Who Is Moderna?
Moderna, Inc. is a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases.
Moderna’s mission is to deliver the greatest possible impact to people through mRNA medicines.
To create a direct order account, visit: www.modernadirect.com
Where is Moderna Located?
Moderna is located in Cambridge, Massachusetts, USA.
What Year was Moderna Founded?
Moderna was founded in 2010.
Who is Moderna Owned By?
The top shareholders of Moderna are Robert S. Langer, Stéphane Bancel, Noubar B. Afeyan, Baillie Gifford & Company, and Flagship Pioneering Inc.
Who is on the Moderna Leadership Team?
Stéphane Bancel is the Chief Executive Officer of Moderna.
Moderna Vaccines History
Since 2010, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed.
Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing.
Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.
Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases.
Today, 40 development programs are underway across these therapeutic areas, with over 13 programs having entered the clinic. Moderna has been named a top biopharmaceutical employer by Science for the past six years.
What is mRNA?
In 1960, a group of scientists identified a molecule that carries instructions inside a cell, like a blueprint to make proteins. They called it messenger RNA (mRNA).
The goal became to change that blueprint to help make new proteins and possibly help protect against disease by actually changing how we prevent and fight diseases.
But mRNA was hard to study because it was very fragile. So, the second effort was figuring out how to deliver this fragile molecule to be useful. mRNA needed an “envelope” for protection.
Almost three decades ago scientists began experimenting with surrounding mRNA with a fatty coat to protect it. This effort involved decoding what directions that the print should give the cell once it’s delivered. This happened over many years with many scientists studying many viruses and today the research efforts continue.
Today, Moderna continues to study mRNA to figure out if it’s possible to teach the human body to fight back against disease. Their research aims to figure out ways to design mRNA that your cells can read to make proteins that your body needs but isn’t making for some reason.
You can think of this like antibodies for a virus that your body hasn’t seen yet. In other words, Moderna is studying mRNA to see if one day it could help teach our bodies to make its own medicine.
Is the Moderna COVID-19 Vaccine Available for Young Children?
The Moderna COVID-19 Vaccine, Bivalent is available for individuals 6 months of age and older.
Moderna Vaccines Ordering and Cost Savings With ABS
Medical practices interested in saving money on Moderna’s COVID-19 vaccine, Spikevax™ may do so through their ABS membership.
Moderna now has a direct purchase website. Creating a direct account with Moderna Direct will allow providers to reserve supply, ensure timely delivery, receive resources, and support, and manage your inventory with ease www.modernadirect.com
Moderna’s COVID vaccine will be available as well through authorized distributors.
Moderna, Inc. is a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases.
Moderna’s mission is to deliver the greatest possible impact to people through mRNA medicines.
To create a direct order account, visit: www.modernadirect.com
Where is Moderna Located?
Moderna is located in Cambridge, Massachusetts, USA.
What Year was Moderna Founded?
Moderna was founded in 2010.
Who is Moderna Owned By?
The top shareholders of Moderna are Robert S. Langer, Stéphane Bancel, Noubar B. Afeyan, Baillie Gifford & Company, and Flagship Pioneering Inc.
Who is on the Moderna Leadership Team?
Stéphane Bancel is the Chief Executive Officer of Moderna.
Moderna Vaccines History
Since 2010, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed.
Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing.
Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.
Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases.
Today, 40 development programs are underway across these therapeutic areas, with over 13 programs having entered the clinic. Moderna has been named a top biopharmaceutical employer by Science for the past six years.
What is mRNA?
In 1960, a group of scientists identified a molecule that carries instructions inside a cell, like a blueprint to make proteins. They called it messenger RNA (mRNA).
The goal became to change that blueprint to help make new proteins and possibly help protect against disease by actually changing how we prevent and fight diseases.
But mRNA was hard to study because it was very fragile. So, the second effort was figuring out how to deliver this fragile molecule to be useful. mRNA needed an “envelope” for protection.
Almost three decades ago scientists began experimenting with surrounding mRNA with a fatty coat to protect it. This effort involved decoding what directions that the print should give the cell once it’s delivered. This happened over many years with many scientists studying many viruses and today the research efforts continue.
Today, Moderna continues to study mRNA to figure out if it’s possible to teach the human body to fight back against disease. Their research aims to figure out ways to design mRNA that your cells can read to make proteins that your body needs but isn’t making for some reason.
You can think of this like antibodies for a virus that your body hasn’t seen yet. In other words, Moderna is studying mRNA to see if one day it could help teach our bodies to make its own medicine.
Is the Moderna COVID-19 Vaccine Available for Young Children?
The Moderna COVID-19 Vaccine, Bivalent is available for individuals 6 months of age and older.
Moderna Vaccines Ordering and Cost Savings With ABS
Medical practices interested in saving money on Moderna’s COVID-19 vaccine, Spikevax™ may do so through their ABS membership.
Moderna now has a direct purchase website. Creating a direct account with Moderna Direct will allow providers to reserve supply, ensure timely delivery, receive resources, and support, and manage your inventory with ease www.modernadirect.com
Moderna’s COVID vaccine will be available as well through authorized distributors.
Who Is Novavax?
Novavax is a biotech company based in Maryland that focuses on vaccines. We use protein-based technology to help protect people across the globe from emerging infectious diseases.
Why Novavax?
What Vaccines Are Made By Novavax?
Novavax is a biotech company based in Maryland that focuses on vaccines. We use protein-based technology to help protect people across the globe from emerging infectious diseases.
Why Novavax?
The Novavax vaccine is the only protein-based vaccine that helps protect against COVID. It’s based on well-established technology that’s been used before in other vaccines, like those for the flu, RSV, hepatitis B, and whooping cough.
What Vaccines Are Made By Novavax?
Novavax makes a Covid-19 vaccine. The Novavax vaccine is a protein-based vaccine. It uses technology similar to what’s used in some vaccines for hepatitis B and the flu. The Novavax vaccine uses traditional, protein-based technology and is a non-mRNA option.
Who Is Pfizer?
Pfizer has played a critical role in healthcare for more than a century and now is helping to usher in a new era of vaccine development. As a global leader in pneumococcal disease prevention, Pfizer will continue to push the boundaries of innovation. Not only has Pfizer developed Trumenba, to prevent meningococcal group B disease, they are currently working on a vaccine for Staphylococcus aureus, the leading cause of hospital-acquired infections. The company is also well known for bringing Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) and Prevnar 20® (Pneumococcal 20-valent Conjugate Vaccine) to market.
Where is Pfizer Located?
Pfizer Inc is an American multinational pharmaceutical and biotechnology corporation headquartered in Manhattan, New York City, USA.
Who is Pfizer Owned By?
The largest shareholders of Pfizer Inc are owned by institutional investors including The Vanguard Group, Inc., BlackRock Fund Advisors, SSgA Funds Management, Capital Research & Management Company, Wellington Management Co. LLP, Geode Capital Management LLC, and Charles Schwab Investment Management.
Pfizer Vaccines History
In 1849 cousins Charles Pfizer and Charles Erhart founded Charles Pfizer & Company in a red brick building in Brooklyn, NY.
Pfizer has a long history in vaccine research and development, including a pivotal role in the eradication of polio and smallpox. Through the development of innovative delivery systems and technologies (the term often used is “novel vaccines”), we’ve created innovations for preventing deadly bacterial infections like those caused by S. pneumoniae and N. meningitidis.
In 2020-2021 Pfizer leads the world in developing a vaccine and treatment in response to the COVID-19 pandemic and commits to lightspeed manufacturing to expand vaccine and treatment access to people around the world.
Pfizer’s Vaccine Research & Development program includes an ongoing focus on the prevention of pneumococcal disease. They’re also advancing vaccines for additional serious childhood, adolescent and adult infections, including meningococcal disease, influenza, Lyme disease, respiratory syncytial virus (RSV), and C difficile.
What is the Pfizer Vaccine Adherence in Kids (VAKs) Program?
Pediatric vaccination has demonstrated proven value in reducing the rate of vaccine-preventable diseases. However, improving vaccine adherence remains a challenge in pediatric health care delivery. Pfizer’s Vaccine Adherence in Kids (VAKs) program can help support vaccination and overall health care for your pediatric patients. The program includes a reminder recall program with a variety of outreach options that span multiple communication channels. Let Pfizer help you reach your patients with their Vaccine Adherence in Kids (VAKs) program.
What Vaccines Are Made By Pfizer?
Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) is a vaccine approved for children 6 weeks through adults for the prevention of pneumococcal pneumonia and invasive disease caused by 13 Streptococcus pneumoniae strains (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). See full prescribing information for specific indications and more.
Prevnar 20® (Pneumococcal 20-valent Conjugate Vaccine) is a vaccine approved for the prevention of invasive disease caused by 20 Streptococcus pneumoniae strains (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F) in individuals 6 weeks and older.
Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) eligible for people 6 months of age or older. This COVID-19 vaccine has not been approved or licensed by FDA, but has been authorized for emergency use by FDA, under an EUA to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals aged 6 months of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b) (1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.
COVID-19 vaccines from BioNTech and Pfizer, which are based on BioNTech proprietary mRNA technology, were developed by both BioNTech and Pfizer.
PFIZER® is a registered trademark of Pfizer Inc.
TRUMENBA® (Meningococcal Group B Vaccine), is the first FDA-approved vaccine for active immunization to prevent invasive disease caused by Neisseria meningitidis group B. It is indicated for individuals 10 through 25 years of age. To learn more about Trumenba please visit here.
TRUMENBA® is a registered trademark of Wyeth LLC.
Pfizer Vaccines Ordering
If you do not have a direct account with Pfizer, you may download the form here – Pfizer Direct Account form. ABS will need your new account number once one is provided to you from Pfizer.
ABS members currently receive an incredible 19% discount on Trumenba® (Meningococcal Group B Vaccine) when ordered directly from Pfizer vaccines, https://primevaccines.pfizer.com .
Pfizer Vaccines Resources Hub
Pfizer has played a critical role in healthcare for more than a century and now is helping to usher in a new era of vaccine development. As a global leader in pneumococcal disease prevention, Pfizer will continue to push the boundaries of innovation. Not only has Pfizer developed Trumenba, to prevent meningococcal group B disease, they are currently working on a vaccine for Staphylococcus aureus, the leading cause of hospital-acquired infections. The company is also well known for bringing Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) and Prevnar 20® (Pneumococcal 20-valent Conjugate Vaccine) to market.
Where is Pfizer Located?
Pfizer Inc is an American multinational pharmaceutical and biotechnology corporation headquartered in Manhattan, New York City, USA.
Who is Pfizer Owned By?
The largest shareholders of Pfizer Inc are owned by institutional investors including The Vanguard Group, Inc., BlackRock Fund Advisors, SSgA Funds Management, Capital Research & Management Company, Wellington Management Co. LLP, Geode Capital Management LLC, and Charles Schwab Investment Management.
Pfizer Vaccines History
In 1849 cousins Charles Pfizer and Charles Erhart founded Charles Pfizer & Company in a red brick building in Brooklyn, NY.
Pfizer has a long history in vaccine research and development, including a pivotal role in the eradication of polio and smallpox. Through the development of innovative delivery systems and technologies (the term often used is “novel vaccines”), we’ve created innovations for preventing deadly bacterial infections like those caused by S. pneumoniae and N. meningitidis.
In 2020-2021 Pfizer leads the world in developing a vaccine and treatment in response to the COVID-19 pandemic and commits to lightspeed manufacturing to expand vaccine and treatment access to people around the world.
Pfizer’s Vaccine Research & Development program includes an ongoing focus on the prevention of pneumococcal disease. They’re also advancing vaccines for additional serious childhood, adolescent and adult infections, including meningococcal disease, influenza, Lyme disease, respiratory syncytial virus (RSV), and C difficile.
What is the Pfizer Vaccine Adherence in Kids (VAKs) Program?
Pediatric vaccination has demonstrated proven value in reducing the rate of vaccine-preventable diseases. However, improving vaccine adherence remains a challenge in pediatric health care delivery. Pfizer’s Vaccine Adherence in Kids (VAKs) program can help support vaccination and overall health care for your pediatric patients. The program includes a reminder recall program with a variety of outreach options that span multiple communication channels. Let Pfizer help you reach your patients with their Vaccine Adherence in Kids (VAKs) program.
What Vaccines Are Made By Pfizer?
Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) is a vaccine approved for children 6 weeks through adults for the prevention of pneumococcal pneumonia and invasive disease caused by 13 Streptococcus pneumoniae strains (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). See full prescribing information for specific indications and more.
Prevnar 20® (Pneumococcal 20-valent Conjugate Vaccine) is a vaccine approved for the prevention of invasive disease caused by 20 Streptococcus pneumoniae strains (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F) in individuals 6 weeks and older.
Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) eligible for people 6 months of age or older. This COVID-19 vaccine has not been approved or licensed by FDA, but has been authorized for emergency use by FDA, under an EUA to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals aged 6 months of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b) (1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.
COVID-19 vaccines from BioNTech and Pfizer, which are based on BioNTech proprietary mRNA technology, were developed by both BioNTech and Pfizer.
PFIZER® is a registered trademark of Pfizer Inc.
TRUMENBA® (Meningococcal Group B Vaccine), is the first FDA-approved vaccine for active immunization to prevent invasive disease caused by Neisseria meningitidis group B. It is indicated for individuals 10 through 25 years of age. To learn more about Trumenba please visit here.
TRUMENBA® is a registered trademark of Wyeth LLC.
Pfizer Vaccines Ordering
If you do not have a direct account with Pfizer, you may download the form here – Pfizer Direct Account form. ABS will need your new account number once one is provided to you from Pfizer.
ABS members currently receive an incredible 19% discount on Trumenba® (Meningococcal Group B Vaccine) when ordered directly from Pfizer vaccines, https://primevaccines.pfizer.com .
Pfizer Vaccines Resources Hub
Who Is Sanofi Pasteur?
Sanofi Pasteur, the vaccines division of the French multinational pharmaceutical company Sanofi, is the largest company in the world devoted entirely to human vaccines. Sanofi Pasteur’s driving goal is to protect people from infectious diseases by creating safe and effective vaccines.
Why Sanofi?
The company offers the broadest range of Sanofi Pasteur vaccines in the world, providing protection against 20 bacterial and viral diseases and distributes more than 1.6 billion doses of vaccine each year, making it possible to vaccinate more than 500 million people across the globe.
What Vaccines Does Sanofi Pasteur Make?
Sanofi Pasteur Vaccines List – The following adult, adolescent, pediatric and travel vaccines are available:
Where Is Sanofi Pasteur Located?
Sanofi is headquartered in Lyon, France with flagship locations in Bridgewater, NJ and Cambridge, MA in the United States
Where is the Sanofi Flu Vaccine Manufactured?
Sanofi Pasteur is the world’s largest manufacturer of flu vaccines. Sanofi produces influenza vaccines across five international sites:
Who Owns Sanofi Pasteur?
Sanofi Pasteur’s parent company is the pharmaceutical company, Sanofi.
How To Pronounce Sanofi Pasteur?
Sounds like: Suh-Now-Fee Pa-Stuh
Why Use ABS to Purchase Sanofi Pasteur Vaccines?
Medical Practice Purchasing Group (ABS) is pleased to offer access to Sanofi Pasteur flu vaccines at contracted rates. Due to product pricing confidentiality, we ask that you contact your Sanofi Pasteur Vaccines sales representatives or ABS to obtain product quotations. Purchase Sanofi Pasteur products directly from VaccineShoppe.com or by calling (800) VACCINE (800-822-2463).
Sanofi Pasteur, the vaccines division of the French multinational pharmaceutical company Sanofi, is the largest company in the world devoted entirely to human vaccines. Sanofi Pasteur’s driving goal is to protect people from infectious diseases by creating safe and effective vaccines.
Why Sanofi?
The company offers the broadest range of Sanofi Pasteur vaccines in the world, providing protection against 20 bacterial and viral diseases and distributes more than 1.6 billion doses of vaccine each year, making it possible to vaccinate more than 500 million people across the globe.
What Vaccines Does Sanofi Pasteur Make?
Sanofi Pasteur Vaccines List – The following adult, adolescent, pediatric and travel vaccines are available:
- Vaxelis® (DTaP-IPV-Hib-HepB)
- Adacel® (Tdap)
- Pentacel® (DTaP-IPV-HIB)
- Daptacel® (DTaP)
- Tripedia® (DTaP)
- ActHIB® (HIB)
- Tubersol® 5 TU
- MenQuadfi® (A,C,Y,W)
- IPOL® (IPV)
- Fluzone® (Fluzone – Influenza Vaccine TIV, Fluzone Quadrivalent (QIV), Fluzone High Dose, Fluzone Intradermal)
- YF-VAX® (YF)
- Typhim Vi® (ViCPS)
- Imogam® (RIG)
- Imovax® (HDCV)
- TENIVAC® (TD)
- TheraCys® (BCG)
Where Is Sanofi Pasteur Located?
Sanofi is headquartered in Lyon, France with flagship locations in Bridgewater, NJ and Cambridge, MA in the United States
Where is the Sanofi Flu Vaccine Manufactured?
Sanofi Pasteur is the world’s largest manufacturer of flu vaccines. Sanofi produces influenza vaccines across five international sites:
- Swiftwater, Pennsylvania (United States)
- Pearl River, New York, United States)
- Val-de-Reuil (France)
- Ocoyoacac (Mexico)
- Shenzhen (China)
Who Owns Sanofi Pasteur?
Sanofi Pasteur’s parent company is the pharmaceutical company, Sanofi.
How To Pronounce Sanofi Pasteur?
Sounds like: Suh-Now-Fee Pa-Stuh
Why Use ABS to Purchase Sanofi Pasteur Vaccines?
Medical Practice Purchasing Group (ABS) is pleased to offer access to Sanofi Pasteur flu vaccines at contracted rates. Due to product pricing confidentiality, we ask that you contact your Sanofi Pasteur Vaccines sales representatives or ABS to obtain product quotations. Purchase Sanofi Pasteur products directly from VaccineShoppe.com or by calling (800) VACCINE (800-822-2463).
"Our savings on our malpractice insurance alone were significant. I highly recommend ABS."
Irwin B., M.D. FAAPPediatrics
"Our practice has been a member of ABS now since 2009 and we couldn’t be happier!"
Irwin B., M.D. FAAP